teaser
Michel Delforge MD PhD
Assistant Professor of Haematology
Department of Haematology
University Hospital Leuven
Belgium
E: [email protected]
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal myeloid haemopathies with a complex underlying pathogenesis. MDS is a common haematological disorder that primarily affects the ageing population. Its clinical presentation is related to progressive bone marrow failure, but around 40% of the MDS population also has an increased risk for leukaemic transformation.(1,2) The International Prognostic
